About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 1/2NCT02452307

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

The study evaluates the prostate-specific antigen (PSA) response in HLA-A\*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine...

Lead sponsor: University Hospital Tuebingen•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital Tuebingen

Patients with a biochemical recurrence after initial therapy can be included.

Age

45 - 80 years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•biochemical recurrence after Radical Prostatectomy
•no clinical metastases in CT or bone scan
•HLA-Type: HLA-A\*02 positive
•Karnofsky-Performance-Index \>70
•Age \>45 / \<80 years
•no prior or ongoing hormonal therapy
•no ongoing radiation therapy
•Serum-Creatinine \<2mg/dl; Bilirubin: \<2gm/dl
•no history of allergy or chronic obstructive lung disease (COLD)

Exclusion Criteria

•Patients unable to consent
•Karnofsky-Performance-Index \<70
•known allergy or COLD
•presence of secondary malignancy
•prior or ongoing hormonal treatment
•ongoing radiotherapy
•immunosuppressive medication
•seizure

Related studies

RECRUITINGPhase 2

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

NCT07365423 · Recurrent Prostate Cancer

A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer

NCT06202248 · Non-metastatic Prostate Cancer, Locally Recurrent Prostate Cancer

Active Not RecruitingPhase 1

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

NCT01923506 · Recurrent Prostate Cancer, Stage I Prostate Cancer, and more

Not Yet RecruitingNA

Treatment of Locally Recurrent Prostate Cancer

NCT07290998 · Prostate Cancer, Recurrent Prostate Cancer, and more

Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT02050906 · Recurrent Prostate Cancer, Stage IV Prostate Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 17, 2017Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE1/PHASE2

Enrollment36

Start dateApr 2004

Last updatedAug 17, 2017

Condition

Recurrent Prostate Cancer

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions